Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Biohit Oyj Comments on FY 2013 and H1 2014 Earnings Guidance
Biohit Oyj announced that it expects to achieve a positive result during fiscal year 2013 or in the first half of fiscal year 2014.
Latest Developments for Biohit Oyj
- Biohit Oyj Comments On FY 2013 Sales Guidance and FY 2014 Earnings Guidance
- Biohit Oyj Announces Results of GastroPanel Screening in Cooperation with Medical Center of the President's Affairs Administration of the Republic of Kazakhstan
- Biohit Oyj Completes Acquisition of Euroclone and Forms New Subsidiary
- Biohit Oyj Acquires Italian Diagnostics Distributor and Forms Wholly-Owned Subsidiary through Euroclone Gastro; Expects Positive Earnings in FY 2014 Instead of FY 2013 or H1 2014
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters